ATE515258T1 - Mukosales verabreichungssytem - Google Patents

Mukosales verabreichungssytem

Info

Publication number
ATE515258T1
ATE515258T1 AT00901497T AT00901497T ATE515258T1 AT E515258 T1 ATE515258 T1 AT E515258T1 AT 00901497 T AT00901497 T AT 00901497T AT 00901497 T AT00901497 T AT 00901497T AT E515258 T1 ATE515258 T1 AT E515258T1
Authority
AT
Austria
Prior art keywords
compositions
vaccines
formulations
methods
well
Prior art date
Application number
AT00901497T
Other languages
German (de)
English (en)
Inventor
Hans Ipsen
Rahbek Janne Uldal
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alk Abello As filed Critical Alk Abello As
Application granted granted Critical
Publication of ATE515258T1 publication Critical patent/ATE515258T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Vending Machines For Individual Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00901497T 1999-02-05 2000-02-04 Mukosales verabreichungssytem ATE515258T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11889699P 1999-02-05 1999-02-05
DKPA199900155 1999-02-05
PCT/DK2000/000049 WO2000045847A1 (en) 1999-02-05 2000-02-04 Novel mucosal delivery system

Publications (1)

Publication Number Publication Date
ATE515258T1 true ATE515258T1 (de) 2011-07-15

Family

ID=26063341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901497T ATE515258T1 (de) 1999-02-05 2000-02-04 Mukosales verabreichungssytem

Country Status (10)

Country Link
EP (1) EP1146906B1 (enExample)
JP (1) JP2003517452A (enExample)
CN (1) CN1338947B (enExample)
AT (1) ATE515258T1 (enExample)
AU (1) AU771552B2 (enExample)
CA (1) CA2361377C (enExample)
DK (1) DK1146906T3 (enExample)
ES (1) ES2368987T3 (enExample)
HK (1) HK1041219B (enExample)
WO (1) WO2000045847A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2330507T3 (es) * 2000-08-09 2009-12-11 Alk-Abello A/S Formulaciones parenterales de vacuna y usos de la mismas.
DK2116257T3 (da) 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
AU2004203772B2 (en) * 2003-01-07 2009-07-16 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
DE602005021388D1 (de) * 2004-11-10 2010-07-01 Alk Abello As Verfahren für die präventive behandlung von allergien durch verabreichung einer allergie-vakzine auf die schleimhäute
US20090155351A1 (en) * 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
DK1814516T3 (da) * 2005-11-04 2013-03-25 Alk Abello As Anvendelse af en flydende allergivaccineformulering til oromucosal indgivelse
US20090297564A1 (en) * 2005-11-04 2009-12-03 Domingo Barber Hernandez Use of a Liquid Allergy Vaccine Formulation for Oromucosal Administration
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system
BR112021025025A2 (pt) * 2019-06-11 2022-02-22 Glaxosmithkline Biologicals Sa Formulações de vacinas de mucosa
CN111658611B (zh) * 2020-04-13 2021-06-01 四川大学 一种基于微乳的疫苗递送系统及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3329564A (en) 1965-06-28 1967-07-04 Parke Davis & Co Antacid preparations and means of producing the same
DE2126957B2 (de) 1971-05-29 1977-07-07 Schettler, Hermann, Dr, East Lan sing, Mich (VStA) Verfahren zur herstellung von impfstoffen gegen gaensehepatitis
US4233288A (en) * 1979-03-12 1980-11-11 Cornell John A Gum emulsified liquid package for delivering and preserving liquid content in the mouth
JPS61238728A (ja) 1985-04-16 1986-10-24 Mitsui Norin Kk 茶葉抽出物と活性水酸化アルミニウムとの抗潰瘍性複合体
IL84167A (en) 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
JPH02124832A (ja) * 1988-07-08 1990-05-14 Toray Ind Inc インターヘェロンβ組成物
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JP3132863B2 (ja) * 1991-10-24 2001-02-05 富山化学工業株式会社 徐放性口腔用軟膏
US5360792A (en) 1991-12-20 1994-11-01 Greenwich Pharmaceuticals Incorporated Anti-proliferative and anti-inflammatory compounds: 5- or 6-deoxy hexose monosaccharides having a saturated nitrogen-containing heterocycle at the 5- or 6-position bound through the nitrogen atom
US5972336A (en) * 1992-11-03 1999-10-26 Oravax Merieux Co. Urease-based vaccine against helicobacter infection
JP3880063B2 (ja) 1993-03-18 2007-02-14 シティミューン サイエンシーズ，インコーポレイテッド 生物学的に活性な因子の毒性を低減させる組成物および方法
GB9316745D0 (en) 1993-08-12 1993-09-29 Medeva Holdings Bv Vaccine compositions
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
JP2001515457A (ja) * 1995-06-07 2001-09-18 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 凝集安定化生理活性物質放出用装置
US6221365B1 (en) * 1996-07-26 2001-04-24 American Cyanamid Company NucA protein of Haemophilus influenzae
EP2172216A3 (en) * 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69822542T2 (de) * 1997-04-23 2004-08-05 Pfizer Inc. Verkapslung einer Untereinheit des Bovinen Herpes Virus Typ-1 in wässrigen Lösungsmitteln als Impfstoff.
JPH11216357A (ja) * 1998-02-03 1999-08-10 Tsutsumi Techno Planning Kk 生理活性物質用の吸着担体
JPH11286438A (ja) * 1998-03-31 1999-10-19 Shiseido Co Ltd 徐放性製剤
JPH11302184A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 点鼻用組成物
JPH11322582A (ja) * 1998-05-06 1999-11-24 Dot:Kk 経鼻吸収用鼻粘膜付着・滞留型キャリヤ

Also Published As

Publication number Publication date
CA2361377A1 (en) 2000-08-10
ES2368987T3 (es) 2011-11-24
WO2000045847A8 (en) 2010-12-02
WO2000045847A1 (en) 2000-08-10
AU771552B2 (en) 2004-03-25
CA2361377C (en) 2009-02-03
EP1146906B1 (en) 2011-07-06
EP1146906A1 (en) 2001-10-24
HK1041219A1 (en) 2002-07-05
CN1338947A (zh) 2002-03-06
AU2279700A (en) 2000-08-25
HK1041219B (en) 2011-10-21
CN1338947B (zh) 2012-11-14
JP2003517452A (ja) 2003-05-27
DK1146906T3 (da) 2011-10-24

Similar Documents

Publication Publication Date Title
ATE515258T1 (de) Mukosales verabreichungssytem
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
NO981746D0 (no) Utlevering av biologisk aktive polypeptider
GEP20053602B (en) Aripiprazole for Oral Administration
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
FR2677654B1 (fr) Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
GB0109297D0 (en) Vaccine
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
ATE399022T1 (de) Zusammensetzung und verfahren zur verstärkung der immunantwort antigen-präsentierender zellen
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
WO2000045849A3 (en) Use of cationic lipids to generate anti-tumor immunity
WO2002058535A3 (en) Use of combretastatin a4 and its prodrugs as an immune enhancing therapy
WO2002053149A3 (de) Arzneimittel enthaltend ein polyamin als wirksubstanz
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
ES2148572T3 (es) Derivados hidrosolubles de epipodofilotoxina, su procedimiento de preparacion, su utilizacion a titulo de medicamento, y su utilizacion destinada a los tratamientos anticancerosos.
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
AU6942896A (en) Use of muteins of wild-type cytokines as immunogens
MY137709A (en) Method for obtaining antigenic structures of high cross reactivity and their use in formulations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties